



Patient Name : Mr.RAJEEV RANJAN
Age/Gender : 32 Y 10 M 11 D/M

UHID/MR No : CSAR.0000061216 Visit ID : CJPNOPV177497

VISILID : CJPNOPV 1772

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 02:05PM Reported : 23/Sep/2023 04:11PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

| ARCOFEMI - MEDIWHEEL - F | ULL BODY ANNUAL | L PLUS MALE - | 2D ECHO - PAN INDIA | - FY2324 | Ī |
|--------------------------|-----------------|---------------|---------------------|----------|---|
| Test Name | Result | Unit | Bio. Ref. Range | Method | |

| HAEMOGLOBIN | 13.4 | g/dL | 13-17 | Spectrophotometer |
|----------------------------------|--------|---------------|---------------|--------------------------------|
| | | | | |
| PCV | 40.40 | % | 40-50 | Electronic pulse & Calculation |
| RBC COUNT | 4.68 | Million/cu.mm | 4.5-5.5 | Electrical Impedence |
| MCV | 86 | fL | 83-101 | Calculated |
| MCH | 28.7 | pg | 27-32 | Calculated |
| MCHC | 33.2 | g/dL | 31.5-34.5 | Calculated |
| R.D.W | 13.8 | % | 11.6-14 | Calculated |
| TOTAL LEUCOCYTE COUNT (TLC) | 6,100 | cells/cu.mm | 4000-10000 | Electrical Impedance |
| DIFFERENTIAL LEUCOCYTIC COUNT (D | LC) | | | |
| NEUTROPHILS | 55.1 | % | 40-80 | Electrical Impedance |
| LYMPHOCYTES | 31.6 | % | 20-40 | Electrical Impedance |
| EOSINOPHILS | 6.1 | % | 1-6 | Electrical Impedance |
| MONOCYTES | 7.1 | % | 2-10 | Electrical Impedance |
| BASOPHILS | 0.1 | % | <1-2 | Electrical Impedance |
| ABSOLUTE LEUCOCYTE COUNT | | | | |
| NEUTROPHILS | 3361.1 | Cells/cu.mm | 2000-7000 | Electrical Impedance |
| LYMPHOCYTES | 1927.6 | Cells/cu.mm | 1000-3000 | Electrical Impedance |
| EOSINOPHILS | 372.1 | Cells/cu.mm | 20-500 | Electrical Impedance |
| MONOCYTES | 433.1 | Cells/cu.mm | 200-1000 | Electrical Impedance |
| BASOPHILS | 6.1 | Cells/cu.mm | 0-100 | Electrical Impedance |
| PLATELET COUNT | 172000 | cells/cu.mm | 150000-410000 | Electrical impedence |
| ERYTHROCYTE SEDIMENTATION | 9 | mm at the end | 0-15 | Modified Westegren |
| RATE (ESR) | | of 1 hour | | method |

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Page 1 of 16











Patient Name

: Mr.RAJEEV RANJAN

Age/Gender

: 32 Y 10 M 11 D/M

UHID/MR No

: CSAR.0000061216

Visit ID Ref Doctor : CJPNOPV177497

Emp/Auth/TPA ID

: Dr.SELF : 919591412818 Collected

: 23/Sep/2023 09:32AM

Received

: 23/Sep/2023 02:05PM : 23/Sep/2023 04:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result

Unit

Bio. Ref. Range

Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE.

Page 2 of 16

SIN No:BED230231160

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN

Age/Gender : 32 Y 10 M 11 D/M UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM

Received : 23/Sep/2023 02:05PM Reported : 23/Sep/2023 05:02PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

| ARCOFEMI - MEDIWHEEL - F | ULL BODY ANNUAL | L PLUS MALE - | 2D ECHO - PAN INDIA | - FY2324 | |
|--------------------------|-----------------|---------------|---------------------|----------|--|
| Test Name | Result | Unit | Bio. Ref. Range | Method | |

| BLOOD GROUP ABO AND RH FACT | OR , WHOLE BLOOD EDTA | |
|-----------------------------|-----------------------|--------------------------------|
| BLOOD GROUP TYPE | A | Microplate Hemagglutination |
| Rh TYPE | Positive | Microplate Hemagglutination |

Page 3 of 16

SIN No:BED230231160

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN Age/Gender : 32 Y 10 M 11 D/M UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818

Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 01:45PM Reported : 23/Sep/2023 03:06PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - F | ULL BODY ANNUAL | L PLUS MALE - | 2D ECHO - PAN INDIA | - FY2324 |
|--------------------------|-----------------|---------------|---------------------|----------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| GLUCOSE, FASTING, NAF PLASMA | 106 | mg/dL | 70-100 | HEXOKINASE |
|------------------------------|-----|-------|--------|------------|
|------------------------------|-----|-------|--------|------------|

Result is rechecked. Kindly correlate clinically

Comment:

As per American Diabetes Guidelines, 2023

| Fasting Glucose Values in mg/dL | Interpretation |
|---------------------------------|----------------|
| 70-100 mg/dL | Normal |
| 100-125 mg/dL | Prediabetes |
| ≥126 mg/dL | Diabetes |
| <70 mg/dL | Hypoglycemia |

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

| GLUCOSE, POST PRANDIAL (PP), 2 | 87 | mg/dL | 70-140 | HEXOKINASE |
|----------------------------------|----|-------|--------|------------|
| HOURS, SODIUM FLUORIDE PLASMA (2 | | | | |
| HR) | | | | |

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN, **HPLC**

Page 4 of 16

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN
Age/Gender : 32 Y 10 M 11 D/M
UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM

Received : 23/Sep/2023 01:45PM

Reported : 23/Sep/2023 03:06PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

| DEPARTMENT OF BIOCHEMISTRY | | | | | | |
|--|--|--|--|--|--|--|
| ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 | | | | | | |
| Test Name Result Unit Bio. Ref. Range Method | | | | | | |
| WHOLE BLOOD EDTA | | | | | | |
| STIMATED AVERAGE GLUCOSE (eAG) , 100 mg/dL Calculated //HOLE BLOOD EDTA | | | | | | |

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

| REFERENCE GROUP | HBA1C % |
|------------------------|-----------|
| NON DIABETIC | <5.7 |
| PREDIABETES | 5.7 - 6.4 |
| DIABETES | ≥ 6.5 |
| DIABETICS | |
| EXCELLENT CONTROL | 6 – 7 |
| FAIR TO GOOD CONTROL | 7 - 8 |
| UNSATISFACTORY CONTROL | 8 - 10 |
| POOR CONTROL | >10 |

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 16







Patient Name

: Mr.RAJEEV RANJAN

Age/Gender

: 32 Y 10 M 11 D/M

UHID/MR No

: CSAR.0000061216

Visit ID

: CJPNOPV177497

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 919591412818

Collected

: 23/Sep/2023 09:32AM

Received

: 23/Sep/2023 01:45PM : 23/Sep/2023 03:06PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

Page 6 of 16



SIN No:PLF02031596,PLP1371717,EDT230087483

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN - U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







Patient Name : Mr.RAJEEV RANJAN
Age/Gender : 32 Y 10 M 11 D/M

UHID/MR No : CSAR.0000061216 Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM
Received : 23/Sep/2023 01:54PM
Reported : 23/Sep/2023 03:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| | | 2.0 0.1201.1 | | | | |
|--|--------|--------------|-----------------|--------|--|--|
| ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 | | | | | | |
| Test Name | Result | Unit | Bio. Ref. Range | Method | | |

| LIPID PROFILE , SERUM | | | | |
|-----------------------|------|-------|--------|-------------------------------|
| TOTAL CHOLESTEROL | 247 | mg/dL | <200 | CHO-POD |
| TRIGLYCERIDES | 158 | mg/dL | <150 | GPO-POD |
| HDL CHOLESTEROL | 48 | mg/dL | 40-60 | Enzymatic Immunoinhibition |
| NON-HDL CHOLESTEROL | 199 | mg/dL | <130 | Calculated |
| LDL CHOLESTEROL | 167 | mg/dL | <100 | Calculated |
| VLDL CHOLESTEROL | 31.6 | mg/dL | <30 | Calculated |
| CHOL / HDL RATIO | 5.14 | | 0-4.97 | Calculated |

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

| | Desirable | Borderline High | High | Very High |
|------------------------|--|-----------------|-----------|-----------|
| TOTAL CHOLESTEROL | < 200 | 200 - 239 | ≥ 240 | |
| TRIGLYCERIDES | <150 | 150 - 199 | 200 - 499 | ≥ 500 |
| | Optimal < 100 Near Optimal 100-129 | 130 - 159 | 160 - 189 | ≥ 190 |
| HDL | ≥ 60 | | | |
| INCIN-HILL CHOLESTEROL | Optimal <130; Above Optimal 130-159 | 160-189 | 190-219 | >220 |

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when

Page 7 of 16







Patient Name : Mr.RAJEEV RANJAN

Age/Gender : 32 Y 10 M 11 D/M

UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 01:54PM

Received : 23/Sep/2023 01:54PM Reported : 23/Sep/2023 03:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

Triglycerides are below 350 mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 8 of 16

SIN No:SE04490297

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN

Age/Gender : 32 Y 10 M 11 D/M UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 01:54PM

Reported : 23/Sep/2023 03:18PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ADOOFFIAL MEDIANIESI S | THE BODY AND HA | DI IIO MALE | OD FOLIO DANIMBIA | E)/0004 |
|--------------------------|-----------------|---------------|---------------------|----------|
| ARCOFEMI - MEDIWHEEL - F | ULL BODY ANNUAL | L PLUS MALE - | 2D ECHO - PAN INDIA | - FY2324 |
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| LIVER FUNCTION TEST (LFT), SERUM | | | | |
|---------------------------------------|-------|-------|---------|-----------------------|
| BILIRUBIN, TOTAL | 0.53 | mg/dL | 0.3–1.2 | DPD |
| BILIRUBIN CONJUGATED (DIRECT) | 0.09 | mg/dL | <0.2 | DPD |
| BILIRUBIN (INDIRECT) | 0.44 | mg/dL | 0.0-1.1 | Dual Wavelength |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) | 76 | U/L | <50 | IFCC |
| ASPARTATE AMINOTRANSFERASE (AST/SGOT) | 42.0 | U/L | <50 | IFCC |
| ALKALINE PHOSPHATASE | 82.00 | U/L | 30-120 | IFCC |
| PROTEIN, TOTAL | 6.55 | g/dL | 6.6-8.3 | Biuret |
| ALBUMIN | 4.30 | g/dL | 3.5-5.2 | BROMO CRESOL GREEN |
| GLOBULIN | 2.25 | g/dĹ | 2.0-3.5 | Calculated |
| A/G RATIO | 1.91 | | 0.9-2.0 | Calculated |

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

- 1. Hepatocellular Injury:
- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen

to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.

Page 9 of 16







Method

Patient Name : Mr.RAJEEV RANJAN Age/Gender : 32 Y 10 M 11 D/M

UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 01:54PM

Reported : 23/Sep/2023 03:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range

• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

- 3. Synthetic function impairment:
- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 10 of 16



SIN No:SE04490297

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN

Age/Gender : 32 Y 10 M 11 D/M

UHID/MR No : CSAR.0000061216

Test Name

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818

Collected : 23/Sep/2023 09:32AM Received : 23/Sep/2023 01:54PM Reported : 23/Sep/2023 03:18PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Result Unit Bio. Ref. Range Method

| RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM | | | | | |
|---|-------|--------|-------------|-----------------------------|--|
| CREATININE | 0.78 | mg/dL | 0.72 – 1.18 | JAFFE METHOD | |
| UREA | 20.80 | mg/dL | 17-43 | GLDH, Kinetic Assay | |
| BLOOD UREA NITROGEN | 9.7 | mg/dL | 8.0 - 23.0 | Calculated | |
| URIC ACID | 5.86 | mg/dL | 3.5–7.2 | Uricase PAP | |
| CALCIUM | 9.30 | mg/dL | 8.8-10.6 | Arsenazo III | |
| PHOSPHORUS, INORGANIC | 3.04 | mg/dL | 2.5-4.5 | Phosphomolybdate Complex | |
| SODIUM | 138 | mmol/L | 136–146 | ISE (Indirect) | |
| POTASSIUM | 4.1 | mmol/L | 3.5–5.1 | ISE (Indirect) | |
| CHLORIDE | 108 | mmol/L | 101–109 | ISE (Indirect) | |

Page 11 of 16



SIN No:SE04490297

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name

: Mr.RAJEEV RANJAN

Age/Gender

: 32 Y 10 M 11 D/M

UHID/MR No

: CSAR.0000061216

Visit ID Ref Doctor : CJPNOPV177497

Emp/Auth/TPA ID

: Dr.SELF : 919591412818 Collected

: 23/Sep/2023 09:32AM

Received

: 23/Sep/2023 01:54PM : 23/Sep/2023 03:18PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - F | ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 | | | | | |
|--------------------------|--|------|-----------------|--------|--|--|
| Test Name | Result | Unit | Bio. Ref. Range | Method | | |

| GAMMA GLUTAMYL TRANSPEPTIDASE | 17.00 | U/L | <55 | IFCC | |
|-------------------------------|-------|-----|-----|------|--|
| (GGT) , SERUM | | | | | |

Page 12 of 16



SIN No:SE04490297

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN
Age/Gender : 32 Y 10 M 11 D/M
UHID/MR No : CSAR.0000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM
Received : 23/Sep/2023 01:53PM
Reported : 23/Sep/2023 03:13PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

| Test Name | Result | Unit | Bio. Ref. Range | Method |
|-----------|--------|------|-----------------|--------|
| | | | | |

| THYROID PROFILE TOTAL (T3, T4, TSH) , | SERUM |
|---------------------------------------|-------|
| TRI-IODOTHYRONINE (T3, TOTAL) | |
| TRI-IODOTHYRONINE (T3, TOTAL) | |

| TRI-IODOTHYRONINE (T3, TOTAL) | 1.29 | ng/mL | 0.64-1.52 | CMIA |
|-----------------------------------|-------|--------|------------|------|
| THYROXINE (T4, TOTAL) | 9.81 | μg/dL | 4.87-11.72 | CMIA |
| THYROID STIMULATING HORMONE (TSH) | 1.270 | μIU/mL | 0.35-4.94 | CMIA |

Comment:

Note:

| For pregnant females | Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association) |
|----------------------|--|
| First trimester | 0.1 - 2.5 |
| Second trimester | 0.2 - 3.0 |
| Third trimester | 0.3 - 3.0 |

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

| TSH | Т3 | T4 | FT4 | Conditions |
|-------|------|------|------|---|
| High | Low | Low | Low | Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis |
| High | N | N | IN | Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy. |
| N/Low | Low | Low | Low | Secondary and Tertiary Hypothyroidism |
| Low | High | High | High | Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy |
| Low | N | N | N | Subclinical Hyperthyroidism |
| Low | Low | Low | Low | Central Hypothyroidism, Treatment with Hyperthyroidism |

Page 13 of 16







Patient Name : N

: Mr.RAJEEV RANJAN

Age/Gender UHID/MR No : 32 Y 10 M 11 D/M : CSAR.0000061216

Visit ID

: CJPNOPV177497

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID :

: 919591412818

Collected

: 23/Sep/2023 09:32AM

Received

: 23/Sep/2023 01:53PM

Reported

Status

: 23/Sep/2023 03:13PM

Sponsor Name

: Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

| Low | N | High | High | Thyroiditis, Interfering Antibodies |
|-------|------|------|------|--|
| N/Low | High | N | N | T3 Thyrotoxicosis, Non thyroidal causes |
| High | High | High | High | Pituitary Adenoma: TSHoma/Thyrotropinoma |

Page 14 of 16



SIN No:SPL23135696

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name : Mr.RAJEEV RANJAN

Age/Gender : 32 Y 10 M 11 D/M UHID/MR No : CSAR.000061216

Visit ID : CJPNOPV177497

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 919591412818 Collected : 23/Sep/2023 09:32AM
Received : 23/Sep/2023 01:16PM
Reported : 23/Sep/2023 04:04PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

| COMPLETE URINE EXAMINATION (CI | JE) , URINE | | | |
|--------------------------------|--------------------|------|------------------|-----------------------------|
| PHYSICAL EXAMINATION | | | | |
| COLOUR | PALE YELLOW | | PALE YELLOW | Visual |
| TRANSPARENCY | CLEAR | | CLEAR | Visual |
| рН | 5.5 | | 5-7.5 | DOUBLE INDICATOR |
| SP. GRAVITY | 1.025 | | 1.002-1.030 | Bromothymol Blue |
| BIOCHEMICAL EXAMINATION | | | | |
| URINE PROTEIN | NEGATIVE | | NEGATIVE | PROTEIN ERROR OF INDICATOR |
| GLUCOSE | NEGATIVE | | NEGATIVE | GLUCOSE OXIDASE |
| URINE BILIRUBIN | NEGATIVE | | NEGATIVE | AZO COUPLING REACTION |
| URINE KETONES (RANDOM) | NEGATIVE | | NEGATIVE | SODIUM NITRO PRUSSIDE |
| UROBILINOGEN | NORMAL | | NORMAL | MODIFED EHRLICH REACTION |
| BLOOD | NEGATIVE | | NEGATIVE | Peroxidase |
| NITRITE | NEGATIVE | | NEGATIVE | Diazotization |
| LEUCOCYTE ESTERASE | NEGATIVE | | NEGATIVE | LEUCOCYTE ESTERASE |
| CENTRIFUGED SEDIMENT WET MO | UNT AND MICROSCOPY | | | |
| PUS CELLS | 2-3 | /hpf | 0-5 | Microscopy |
| EPITHELIAL CELLS | 1-2 | /hpf | <10 | MICROSCOPY |
| RBC | NIL | /hpf | 0-2 | MICROSCOPY |
| CASTS | NIL | | 0-2 Hyaline Cast | MICROSCOPY |
| CRYSTALS | ABSENT | | ABSENT | MICROSCOPY |

Page 15 of 16



SIN No:UR2189441

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







Patient Name

: Mr.RAJEEV RANJAN

Age/Gender

: 32 Y 10 M 11 D/M

UHID/MR No

: CSAR.0000061216

Visit ID

: CJPNOPV177497

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 919591412818 Collected

: 23/Sep/2023 09:32AM

Received

: 23/Sep/2023 12:29PM

Reported

Status

: 23/Sep/2023 03:17PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

| DEDADTMENT | OF CLINICA | AL PATHOLOGY |
|------------|------------|-------------------------------|
| DEPARTMENT | | 11 PAIH() ()(₇ Y |

Test Name Result Unit Bio. Ref. Range Method

URINE GLUCOSE(POST PRANDIAL)

NEGATIVE

NEGATIVE

Dipstick

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

Drasania 8xp Dr PRASANNA B.K.P Md.Path.Pathologist

DR. SHIVARAJA SHETTY M.B.B.S,M.D(Biochemistry)

CONSULTANT BIOCHEMIST

Dr. Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist


M.B.B.S, M.D(Pathology)

Consultant Pathologist


Page 16 of 16


SIN No:UPP015517,UF009503 NABL renewal accreditation under process


THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE




| Asian Male Max Asian Male Max Asian Male Max Asian Male Max Asian Asia | To do not only | • | | 4 | 77.07 | | | | |
|--|-----------------|-------------------------|---------|--------------|---------------|--------------|-------------|-------------------------|-----|
| Main Male Max BP 150 80 Maximum workload: Cammon for Termination: Maximum workload: Cammon for Termination: Common for Termination: Cammon for Termination: | Visit MEDIWHEEL | TEEL | | <u> </u> | ax HR: 160bpn | 1 85% of max | Potal Exerc | ise time: 9:01 88bpm | |
| Case Comments Comment Commen | 2 | 32years | Male | , <u>v</u> | ax BP: 150/80 | | Maximum v | vorkload: 10.1METS | |
| CAM SCREENING CAMAGINA THAT PROPERTIES | *13:08:42 | | | . O k | mments: GOC | D EFFORT A | VD TOLER | ENCE | |
| AD SCREENING Time in Speed Circle WorkLand HR BP Name Stage (mph) Stage (mph) Stage (METS) (bpm) STACE 1 3.00 1.7 0.0 4.6 122 130/8 STACE 2 3.00 2.5 2.0 10.2 180 340/8 STACE 4 0.01 3.4 1.0 11.2 130/8 STACE 4 1.0 3.4 1.0 11.2 130/8 Post 1.0 3.4 1.0 1.2 130/8 Post 1.0 3.4 1.0 1.2 130/8 Chomitimad Library Continued Uncontinued | | Dofamod his epite | | . v. v | O ANGINA AN | D ARRYTHMI | A NOTED | | |
| Stage Time in Speed Grede WorkLoad HR BP | | Test ind: CAD SCREENING | | | MT IS NEGATI | VE FOR INDI | CBLE ISC | HEMIA | |
| Name Stage (mph) SUPINE SUPINE 0.49 0.8 0.0 1.7 0.0 1.2 92 2008 STAGE 1 3:00 2.5 STAGE 3 3:00 3.4 1.0 1.1 1.0 1.1 1.0 1.1 1.0 1.1 1.0 | | Stage | Time in | Speed | Grade | WorkLoad | 景 | ВР | |
| SUPINE STAGE 1 STAGE 2 STAGE 2 STAGE 3 STAGE 3 STAGE 4 STAG | | Name | Stage | (mph) | 28 | (METS) | (bpm) | (mmHg) | |
| STAGE 1 3:00 1.7 20.3 1.6 122 130/8 STAGE 2 3:00 2.5 7.0 139 140/8 STAGE 3 3:00 3.4 1.0 10.1 180 150/8 Post 1:30 **: 7.5 7.5 127/8 NORMAL 20/8 NORMAL 20/8 NORMAL 20/8 NORMAL 20/8 NORMAL 20/8 Unconfirmed | PRETEST | SUPINE | 0:49 | 0.8 | 0.0 | i.s | 92 | 120/80 | |
| STAGE 2 3.00 2.5 1.3 7.0 139 140/8 STAGE 3 3.00 3.4 1.4 1.0 10.1 180 150/8 STAGE 4 0.01 3.4 1.3 10.1 180 150/8 Post 1.30 5.7 120/8 NORAGA L January January Unconfirmed | EXERCISE | | 3:00 | 1.7 | Ţ.0.0 | | 122 | 130/80 | |
| STAGE 4 0:01 3.4 1.0 150/8 STAGE 4 1:30 5:- 150/8 Post 1:30 5:- 120/8 NOR 55/8 1:37 120/8 NOR 55/8 127 120/8 STAGE 56/8 127 120/8 NOR 56/8 127 120/8 Unonfirmed | | STAGE 2 | 3:00 | 2.5 | : : : | | 139 | 740/80 | |
| STACE 4 0:01 3.4 1.5 10.1 160 150/8 Post 1:30 **:* 1:3 1:3 1:27 120/8 NOR **:* NOR **:* 127 120/8 3:319/25 3:319/25 Unconfirmed | | STAGE 3 | 3:00 | 3,4 | | 10.1 | 160 | 150/80 | |
| Post 130 *** 127 120/8 NOR *** 127 120/8 NOR *** 127 120/8 Laconfirmed | | STAGE 4 | 0:01 | 3.4 | | , | 160 | 150/80 | |
| HORACAL 3319125 | RECOVERY | Post | 1:30 | * | . * * | 3,3 | 127 | 120/80 | |
| Jalalay Jalay Jalay Jalay Jalah Jalay | | | | | NOR96 | | | | |
| Sales | | | | | † | | | | |
| Unconfirmed | | | | | 23/9/ | Ž | | | |
| Unconfirmed | | | | | | | | | |
| Unconfirmed | | | | | | | | | |
| Unconfirmed | | | | | | | | | |
| Unconfirmed | | | | | | | | | |
| Unconfirmed | | | | | | | | | |
| | cian: V. | NUTHA | | | Üпс | onfirmed | | MAC55 010A | ~ . |







SELECTED MEDIANS REPORT







Health Check up Booking Request(bobS46082), Beneficiary Code-73395

1 message

Mediwheel <wellness@mediwheel.in>

To: sakshisah5@gmail.com Cc: customercare@mediwheel.in Mon, 11 Sep, 2023 at 11:37 AM



011-41195959

Email:wellness@mediwheel.in

Dear Rajeev,

Thanks for booking Health Checkup and we have required following document for confirmation of booking health checkup.

1. HRM Letter

Please note following instruction for HRM letter.

- 1. For generating permission letter for cashless health check-up in the HR Connect, the path to be followed is given below:
- a) Employee Self Service-> Reimbursement-> Reimbursement application -> Add New value ->Reimbursement Type: Mandatory Health Check-up ā€" Click Add
- b) Select Financial Year 2022-23, Self or Spouse, Claim Type Cashless and Submit
- c) After submission, click print button to generate Permission Letter

Booking Date

: 11-09-2023

Health Check up

Name

: Arcofemi MediWheel Full Body Annual Plus Male 2D ECHO (Metro)

Name of

Diagnostic/Hospital

Apollo Clinic - JP Nagar

Address of

House List No. 22, BNR Complex, Sree Rama Layout, Opp: RBI Layout, JP Diagnostic/Hospital Nagar 7th Phase, Kothanur Village, Uttarahalli Hobli, JP nagar - 560078

Appointment Date : 23-09-2023

Preferred Time : 8:00am-8:30am

| | Member Inform | nation | |
|--------------------|------------------------|----------|--------------|
| Booked Member Name | Age | Gender | Cost(In INR) |
| Rajeev | 32 | Male | Cashless |
| To | otal amount to be paid | Cashless | |

We will get back to you with confirmation update shortly. Please find the package details as attached for your reference.



Age/Gender **Patient Name** : 32 Y/M : Mr. Rajeev Ranjan

: CSAR.0000061216

OP Visit No Reported on : CJPNOPV177497

Sample Collected on

: RAD2106698

Specimen

: 23-09-2023 11:56

Ref Doctor

LRN#

UHID/MR No.

: SELF

Emp/Auth/TPA ID

: 919591412818

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Normal in size and echotexture. No focal lesion seen.

No intra hepatic biliary / venous radicular dilation.

CBD and Main Portal vein appear normal.PV-10 mm.

GALL BLADDER: Well distended. Normal in internal contents. Wall Thickness is normal.

SPLEEN: Normal in size and echotexture. No focal lesion was seen.

PANCREAS: Appeared normal to the visualized extent.

KIDNEYS: Both kidneys are normal in size, shape and outlines Cortico medullary delineation is

maintained. No Hydronephrosis / No calculi.

Right kidney measures:11.0 x 2.0 cm. Left kidney measures : 11.1 x 2.0 cm.

URINARY BLADDER: Well distended. Normal in internal contents. Wall thickness is normal.

PROSTATE: Normal in size and echotexture.

Prostate measures :3.5 x 2.8 x 3.0 cms. Volume-16 cc.

No free fluid is seen in the peritoneum. No lymphadenopathy.

IMPRESSION: NORMAL STUDY.

Please Note: No preparation done before scanning.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.



Patient Name : Mr. Rajeev Ranjan Age/Gender : 32 Y/M

 $\frac{\text{Dr. KUSUMA JAYARAM}}{\text{MBBS,DMRD}}$ Radiology



: CJPNOPV177497 : 23-09-2023 11:54

Patient Name : Mr. Rajeev Ranjan Age/Gender : 32 Y/M

UHID/MR No.

: CSAR.0000061216

Sample Collected on

: RAD2106698

Ref Doctor

LRN#

: SELF

Emp/Auth/TPA ID : 919591412818

OP Visit No

Reported on

Specimen

X-RAY CHEST PA

DEPARTMENT OF RADIOLOGY

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION:

No obvious abnormality seen.

Dr. KUSUMA JAYARAM

MBBS,DMRD

Radiology